Regulatory authorities such as the US Food and Drug Administration and European Medicines Agency face continual criticism for their plodding pace of drug approval decisions. In 2009, the last year for which complete data are available, the median time for a standard review of a drug application in the US was 13 months—30% longer than the agency’s target for such reviews. But even with this situation, it’s undeniable that both agencies devote far more human and financial resources to the process than most other countries can afford to spend on their own.
A judge has prohibited Bayer Cropscience from marketing Liberty Link corn, a genetically modified crop resistant to Ignite and Liberty herbicides, in Brazil. If the Leverkusen, Germany–based company fails to suspend marketing, planting, transportation and import immediately, it will be fined R$50,000 ($28,500) a day. This ruling issued in July by an environmental court in the southern state of Parana is only the second time a Brazilian court has overturned a commercial GM crop already approved by the country’s technical commission on biosafety (CTNBio), says the commission’s coordinator Jairon Nascimento. Continue reading Brazil bans Bayer→
Cassava breeds that are resistant to two major viruses could soon be available to farmers in Africa.
Cassava mosaic disease and brown streak disease stunt the growth and rot the roots of crops, respectively.
Mosaic disease alone destroys an estimated 35 million tonnes of African cassava a year — the difference between needing to import food into Africa and achieving food independence, according to researchers at the US-based Donald Danforth Plant Science Center.
The team has shown in the laboratory tests that genetically engineered (GE) tobacco plants resist brown streak disease. Their results will appear in Molecular Plant Pathology next month (August), Claude Fauquet, lead author of the study and director of cassava research at the centre, told SciDev.Net. Continue reading Virus-resistant cassava could be available by 2015→
The African Union has set up a school to educate and train future regulators in genetically modified (GM) crop biosafety. The African Biosafety Network of Expertise (ABNE) was officially launched in April in Ouagadougou, Burkina Faso, with a five-year, $10.4 million grant from the Bill & Melinda Gates Foundation. Continue reading African GM safety drill→
Journalist covering global development by way of science and technology.
Regulatory authorities such as the US Food and Drug Administration and European Medicines Agency face continual criticism for their plodding pace of drug approval decisions. In 2009, the last year for which complete data are available, the median time for a standard review of a drug application in the US was 13 months—30% longer than the agency’s target for such reviews. But even with this situation, it’s undeniable that both agencies devote far more human and financial resources to the process than most other countries can afford to spend on their own.
